Bring back the Pixel Pen!
A stylus, though? Now that could open up the Pixel Tablet to a whole new audience of artists. And in addition to the report above, we should note that Google lists Universal Stylus Initiative support in the spec sheet for the Google Tablet, something backed up by the USI initiative’s latest emailed press release.
"The newest tablet support for USI from Amazon and Google is another milestone for the standard, as we continue to grow into new devices and operating systems," said Alexander Erdman, president of USI."We are very excited to see the adoption of the USI specification in devices running Android, as we continue to drive for a single industry standard for an active stylus.
preferring proprietary technology – the tide may be turning. As Google and Amazon are jumping on board, a USI shift may be on the way for Android, and with it, the platform could become more desirable for artists who have typically gravitated towards Apple’s more pen-friendly platform. A dedicated Pixel Tablet stylus could only help in that regard. We'll let you know if and when Google does make an official announcement.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Taking Google’s sleek Pixel Tablet for a test runThe Google Pixel Tablet is a premium slice of media tech, complete with speaker dock that transforms it into the central hub of a smart home set-up
Read more »
Google Pixel Tablet review: A new home for the same old AndroidA great idea in need of a few software updates
Read more »
Pixel Tablet: Google's latest comes with a twist - but can it find an audience?Google has a history of killing off products that don't set the world alight, from its Stadia gaming platform to its previous Pixel tablet. It hopes its latest effort will find itself an audience by straddling the line between tablet and home hub.
Read more »
The Google Pixel Watch is getting 3 new features – but Samsung and Apple got there firstGoogle Pixel Watch is getting 'At A Glance' to keep up with other watches
Read more »
Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial - BMC Infectious DiseasesBackground Shortly after the Coronavirus disease 2019 (COVID-19) pandemic, a considerable number of recovered patients reported persisting symptoms, especially neuropsychological manifestations, which were later named post-COVID syndrome (PCS). Immune dysregulation was suggested as one of the main mechanisms for PCS. Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that is mostly used to treat depression, anxiety disorders, and obsessive–compulsive disorder, has been suggested as an anti-COVID drug due to its anti-inflammatory effects, mainly through the sigma-1 receptor. Therefore, we aimed to evaluate fluvoxamine's effect on PCS neuropsychiatric symptoms. Method In this double-blind randomized clinical trial, we included confirmed mild to moderate COVID-19 outpatients using polymerase chain reaction (PCR) by an infectious disease specialist. The presence of severe COVID-19 symptoms was evaluated by the infectious disease specialist and included dyspnea, SpO2 30 breaths/min, and lung infiltrates | 50%. Then we performed permuted block randomization and assigned patients 1:1 into two groups to either receive fluvoxamine 100 mg tablet or a placebo daily for 10 days. Eligible patients were evaluated after 12 weeks for the presence of fatigue, as the primary, and other PCS symptoms as secondary outcomes. Results We screened a total of 486 patients from March to June 2022. After 12 weeks, 42 patients receiving fluvoxamine and 43 patients receiving Placebo were evaluated for PCS. Patients had a mean age of 38.5 ± 14.1 and 48% of them were women. Fatigue was significantly lower in the fluvoxamine group (p-value 0.026). No significant differences were observed in other symptoms. Conclusion We concluded that taking fluvoxamine during active COVID-19 can reduce the chance of fatigue but the advantage of fluvoxamine was not observed for other symptoms. Further studies are necessary to confirm these preliminary results.
Read more »
I won Sun prize trip to the Titanic - now I pray missing crew is found aliveSUN reader Peter Bailey won the prize of a lifetime – to join reporter Martin Phillips on a submersible trip to the Titanic. Peter, now 59, of Matlock, Derbys, is praying that the crew of the missi…
Read more »